Home
About Us
About Us
Board of Directors
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
Media Centre
Overview
Latest News
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Investor Newsletters
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2022
2021
2020
2019
2018
6-Jul-2022
FDA grants RPDD to paxaliaib for AT/RT
30-Jun-2022
Kazia progress update
27-Jun-2022
Ceasing to be a substantial holder
27-Jun-2022
Change in substantial holding
24-Jun-2022
Cleansing notice
24-Jun-2022
Application for quotation of securities - KZA
23-Jun-2022
Kazia presentation on paxalisib for childhood brain cancer
23-Jun-2022
Change in substantial holding
17-Jun-2022
Cleansing Notice
17-Jun-2022
Application for quotation of securities - KZA
1
2
3
4
5
Next
